Skip to main content

New Vaccine Development Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986) / Chapter Skim
Currently Skimming:

Appendix D-1: The Prospects for Immunizing Against Dengue Virus
Pages 170-177

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 170...
... With the return of a normal temperature, the vascular permeability phase begins. There also appears to be other severe expressions of dengue virus infection such as a syndrome in which severe hemorrhage appears without increased vascular permeability (Halstead, personal communication, 1985~.
Read the entire page →
From page 171...
... All volunteers responded and none developed dengue-like symptoms (Halstead, personal communication, 1985~. PATHOGEN DESCRIPTION Dengue viruses are togaviruses of the genus flavivirus and are transmitted by the mosquito vector Aedes aegypti.
Read the entire page →
From page 172...
... In tropical Southeast Asia, DHF/DSS has produced 1.3 million hospitalizations and 23,000 deaths in a 30-year period. DHF/DSS incidence is increasing, with a mean annual incidence for the past 5 years of about 60,000 hospitalizations and 1,500 deaths (Halstead, personal communication, 19851.
Read the entire page →
From page 173...
... 173 s~ ~a 0 U1 0 a, o 0 o' In U~ ~o 0 a P~ 1 U~ o ·rl 54 s~ a z o o ·rl U)
Read the entire page →
From page 174...
... Hence, in DHF/DSS endemic areas, 100 percent of the disease burden could be prevented by a vaccine that was 100 percent effective and that could be successfully administered to the entire target population at an early age. Herd immunity has not been studied in dengue infections, but it is possible that the disease burden could be eliminated even if vaccine coverage were not complete.
Read the entire page →
From page 175...
... However, it shares with all other vaccine strains limited growth potential in suitable mammalian cells, and thus the maximum titer of the vaccine probably will be about 105. Any dengue vaccine program must have as major components ongoing epidemiological studies of risk factors, surveillance for DHF/DSS cases among vaccinees, and fundamental immunological studies designed to elucidate the mechanisms of DHF/DSS.
Read the entire page →
From page 176...
... definition of epitopes that induce the formation of protective rather than enhancing antibodies in a manner similar to that demonstrated for yellow fever (Schlesinger et al., 19851. Among the various vaccine approaches discussed above,`the committe chose to evaluate an attenuated live vector virus containing the gene for a broadly cross reacting protective antigen.
Read the entire page →
From page 177...
... 1984. Risk factors in dengue shock syndrome: A prospective epidemiologic study in Rayong, Thailand.
Read the entire page →

Key Terms

  • dengue viruses
  • dengue fever
  • vascular permeability
  • dengue vaccine
  • yellow fever

  • dengue vaccines
  • target population
  • risk factors
  • fetal rhesus
  • lung cells

  • shock syndrome
  • disease burden
  • rhesus lung
  • attenuated dengue
  • dog kidney

  • immune response
  • serial passage
  • protective antigen
  • kidney cells
  • dengue infection

  • virus types
  • percent effective
  • aedes aegypti
  • dengue serotypes
  • dengue endemic

  • dengue shock
  • dengue infections
  • dengue serotype
  • description dengue
  • mononuclear phagocytes


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.